O	0	1	"
O	1	11	Randomised
O	12	22	controlled
O	23	28	trial
O	29	31	of
B-intervention	32	37	scalp
I-intervention	38	45	cooling
O	46	49	for
O	50	53	the
O	54	64	prevention
O	65	67	of
B-condition	68	80	chemotherapy
I-condition	81	88	induced
I-condition	89	97	alopecia
O	97	98	"
O	98	99	.

O	100	110	Randomized
O	111	121	controlled
O	122	128	trials
O	129	130	(
O	130	133	RCT
O	133	134	)
O	135	137	of
O	138	143	scalp
O	144	151	cooling
O	152	153	(
O	153	155	SC
O	155	156	)
O	157	159	to
O	160	167	prevent
O	168	180	chemotherapy
O	181	188	induced
O	189	197	alopecia
O	198	199	(
O	199	202	CIA
O	202	203	)
O	204	207	did
O	208	211	not
O	212	220	evaluate
O	221	224	its
O	225	231	effect
O	232	234	on
O	235	239	hair
O	240	248	regrowth
O	249	250	(
O	250	252	HR
O	252	253	)
O	254	257	and
O	258	261	was
O	262	271	conducted
O	272	274	in
O	275	276	a
O	277	290	predominantly
O	291	297	taxane
O	298	299	(
O	299	300	T
O	300	301	)
O	302	309	treated
O	310	320	population
O	320	321	.

O	322	324	We
O	325	334	conducted
O	335	337	an
O	338	341	RCT
O	342	344	of
O	345	347	SC
O	348	350	in
O	351	352	a
O	353	360	setting
O	361	363	of
O	364	377	anthracycline
O	378	379	(
O	379	380	A
O	380	381	)
O	382	385	and
O	386	392	taxane
O	393	405	chemotherapy
O	406	407	(
O	407	409	CT
O	409	410	)
O	411	414	and
O	415	423	assessed
O	424	427	its
O	428	434	effect
O	435	437	on
O	438	441	CIA
O	442	445	and
O	446	448	HR
O	448	449	.

B-eligibility	450	453	Non
I-eligibility	453	454	-
I-eligibility	454	464	metastatic
I-eligibility	465	471	breast
I-eligibility	472	478	cancer
I-eligibility	479	484	women
I-eligibility	485	495	undergoing
I-eligibility	496	497	(
I-eligibility	497	500	neo
I-eligibility	500	501	)
I-eligibility	502	510	adjuvant
I-eligibility	511	513	CT
O	514	518	were
O	519	529	randomized
O	530	532	to
O	533	540	receive
O	541	543	SC
O	544	549	using
O	550	553	the
O	554	560	Paxman
O	561	566	scalp
O	567	574	cooling
O	575	581	system
O	582	588	during
O	589	594	every
O	595	600	cycle
O	601	603	of
O	604	606	CT
O	606	607	,
O	608	610	or
B-control	611	613	no
I-control	614	616	SC
O	616	617	.

O	618	621	The
O	622	629	primary
O	630	633	end
O	634	639	point
O	640	641	(
O	641	644	PEP
O	644	645	)
O	646	649	was
B-outcome-Measure	650	660	successful
I-outcome-Measure	661	665	hair
I-outcome-Measure	666	678	preservation
I-outcome-Measure	679	680	(
I-outcome-Measure	680	682	HP
I-outcome-Measure	682	683	)
O	684	692	assessed
O	693	703	clinically
O	704	707	and
O	708	710	by
O	711	717	review
O	718	720	of
O	721	732	photographs
O	733	738	after
O	739	741	CT
O	741	742	.

O	743	745	HR
O	746	749	was
O	750	758	assessed
O	759	761	at
O	762	763	6
O	764	767	and
O	768	770	12
O	771	776	weeks
O	776	777	.

B-total-participants	778	780	51
O	781	789	patients
O	790	794	were
O	795	805	randomized
O	806	808	to
O	809	811	SC
O	812	813	(
B-intervention-participants	813	815	34
O	815	816	)
O	817	819	or
O	820	827	control
O	828	831	arm
O	832	833	(
B-control-participants	833	835	17
O	835	836	)
O	837	839	in
O	840	841	a
O	842	843	2
O	843	844	:
O	844	845	1
O	846	851	ratio
O	851	852	.

O	853	859	Twenty
O	859	860	-
O	860	864	five
O	865	866	(
O	866	868	49
O	868	869	%
O	869	870	)
O	871	879	patients
O	880	888	received
O	889	890	A
O	891	899	followed
O	900	902	by
O	903	904	T
O	905	908	and
O	909	912	the
O	913	916	two
O	917	921	arms
O	922	926	were
O	927	935	balanced
O	936	940	with
O	941	948	respect
O	949	951	to
O	952	956	this
O	957	963	factor
O	963	964	.

B-outcome	965	967	HP
I-outcome	968	972	rate
O	973	976	was
O	977	990	significantly
O	991	997	higher
O	998	1000	in
O	1001	1003	SC
O	1004	1007	arm
O	1008	1016	compared
O	1017	1019	to
O	1020	1027	control
O	1028	1031	arm
O	1032	1033	(
B-iv-bin-percent	1033	1035	56
I-iv-bin-percent	1035	1036	.
I-iv-bin-percent	1036	1037	3
I-iv-bin-percent	1037	1038	%
O	1039	1041	vs
B-cv-bin-percent	1042	1043	0
I-cv-bin-percent	1043	1044	%
O	1044	1045	,
O	1046	1047	P
O	1048	1049	=
O	1050	1051	0
O	1051	1052	.
O	1052	1058	000004
O	1058	1059	)
O	1059	1060	.

B-outcome	1061	1063	HR
O	1064	1067	was
O	1068	1074	higher
O	1075	1077	in
O	1078	1080	SC
O	1081	1084	arm
O	1085	1093	compared
O	1094	1096	to
O	1097	1104	control
B-outcome	1105	1107	at
I-outcome	1108	1109	6
I-outcome	1110	1115	weeks
O	1116	1117	(
B-iv-bin-percent	1117	1119	89
I-iv-bin-percent	1119	1120	%
O	1121	1123	vs
B-cv-bin-percent	1124	1126	12
I-cv-bin-percent	1126	1127	%
O	1127	1128	;
O	1129	1130	P
O	1131	1132	<
O	1133	1134	0
O	1134	1135	.
O	1135	1138	001
O	1138	1139	)
O	1140	1143	and
B-outcome	1144	1146	12
I-outcome	1147	1152	weeks
O	1153	1154	(
B-iv-bin-percent	1154	1157	100
I-iv-bin-percent	1157	1158	%
O	1159	1161	vs
B-cv-bin-percent	1162	1164	59
I-cv-bin-percent	1164	1165	%
O	1165	1166	,
O	1167	1168	P
O	1169	1170	=
O	1171	1172	0
O	1172	1173	.
O	1173	1177	0003
O	1177	1178	)
O	1178	1179	.

B-outcome	1180	1184	Loss
I-outcome	1185	1187	of
I-outcome	1188	1192	hair
I-outcome	1193	1195	at
I-outcome	1196	1199	PEP
I-outcome	1200	1210	evaluation
O	1210	1211	,
O	1212	1217	which
O	1218	1221	was
O	1222	1223	a
O	1224	1231	quality
O	1232	1234	of
O	1235	1239	life
O	1240	1247	measure
O	1247	1248	,
O	1249	1252	was
O	1253	1266	significantly
O	1267	1272	lower
O	1273	1275	in
O	1276	1278	SC
O	1279	1285	versus
O	1286	1293	control
O	1294	1297	arm
O	1298	1299	(
B-iv-bin-percent	1299	1301	45
I-iv-bin-percent	1301	1302	%
O	1303	1305	vs
B-cv-bin-percent	1306	1308	82
I-cv-bin-percent	1308	1309	%
O	1309	1310	,
O	1311	1312	P
O	1313	1314	=
O	1315	1316	0
O	1316	1317	.
O	1317	1320	016
O	1320	1321	)
O	1321	1322	.

O	1323	1328	There
O	1329	1333	were
B-outcome	1334	1336	no
I-outcome	1337	1342	grade
I-outcome	1343	1344	3
I-outcome	1344	1345	-
I-outcome	1345	1346	4
I-outcome	1347	1351	cold
I-outcome	1352	1359	related
I-outcome	1360	1367	adverse
I-outcome	1368	1375	effects
O	1375	1376	.

O	1377	1382	Women
O	1383	1387	with
O	1388	1394	breast
O	1395	1401	cancer
O	1402	1411	receiving
O	1412	1413	A
O	1414	1416	or
O	1417	1418	T
O	1419	1431	chemotherapy
O	1432	1441	receiving
O	1442	1444	SC
O	1445	1449	were
O	1450	1463	significantly
O	1464	1468	more
O	1469	1475	likely
O	1476	1478	to
O	1479	1483	have
O	1484	1488	less
O	1489	1493	than
O	1494	1496	50
O	1496	1497	%
O	1498	1502	hair
O	1503	1507	loss
O	1508	1513	after
O	1514	1516	CT
O	1516	1517	,
O	1518	1526	superior
O	1527	1531	hair
O	1532	1540	regrowth
O	1541	1544	and
O	1545	1556	improvement
O	1557	1559	in
O	1560	1567	patient
O	1568	1576	reported
O	1577	1585	outcomes
O	1585	1586	,
O	1587	1591	with
O	1592	1602	acceptable
O	1603	1612	tolerance
O	1612	1613	.

O	1614	1616	It
O	1617	1623	merits
O	1624	1629	wider
O	1630	1635	usage
O	1635	1636	.
